PLX Earnings
Protalix Biotherapeutics Inc
$
1.640
- Overview
- Forecast
- Valuation
- Earnings
Earning Analysis
Welcome to our in-depth analysis of Protalix Biotherapeutics Inc(PLX) earnings, offering investors a detailed look into the company’s financial performance, revenue trends, earnings per share (EPS), and market reactions. This page provides a comprehensive overview of Protalix Biotherapeutics Inc earnings history, forecasts, and key financial metrics, empowering you with the data needed to make informed investment decisions. Whether you're tracking quarterly results, analyzing earnings surprises, or exploring future projections, our detailed breakdown covers it all.
Earnings Forecast
Revenue
EPS
Currency: USD
Actual
Estimate
Surprise Analysis
| FY2025Q2 | 2025-08-14 | Pre-Market | 0.03 | - | - | 13.55M | - | - | - | - |
| FY2025Q1 | 2025-05-09 | Pre-Market | 0.08 | -0.05 | -162.50 | 21.60M | 10.00M | -53.73 | -40.48 | -42.21 |
| FY2024Q4 | 2025-03-17 | Pre-Market | 0.07 | 0.09 | +28.57 | 18.75M | 18.22M | -2.81 | +9.37 | +11.16 |
| FY2024Q2 | 2024-08-14 | Pre-Market | 0.02 | -0.03 | -250.00 | 12.50M | 13.30M | +6.43 | -10.58 | -8.65 |
| FY2024Q1 | 2024-05-10 | - | - | -0.06 | - | 9.20M | 3.68M | -60.03 | -12.00 | -6.40 |
| FY2023Q4 | 2024-03-14 | - | -0.03 | -0.07 | -133.33 | 8.15M | 10.49M | +28.73 | -9.87 | -11.84 |
| FY2023Q3 | 2023-11-06 | - | -0.07 | -0.04 | +42.86 | 7.64M | 10.35M | +35.41 | -18.38 | -27.57 |
| FY2023Q2 | 2023-08-07 | - | -0.04 | 0.21 | +625.00 | 10.22M | 35.08M | +243.13 | +14.46 | +15.66 |
| - | 2023-02-27 | - | -0.15 | -0.07 | +53.33 | - | - | - | +2.75 | +12.64 |
| - | 2022-11-14 | - | -0.15 | -0.07 | +53.33 | - | - | - | +1.90 | +1.90 |
Get winning stock picks in minutes
PLX Earnings Analysis
Our earnings analysis provides a granular look at the company’s performance across recent fiscal quarters, highlighting key metrics such as revenue, EPS, and operating margins. By examining actual results against analyst estimates, we uncover trends and surprises that drive stock price movements, offering valuable insights for both short-term traders and long-term investors.
In the most recent quarter, Protalix Biotherapeutics Inc reported performance for FY2025Q2, announced on 2025-08-14. The company achieved an EPS of , compared to analyst estimates of 0.03 by % . Revenue for the quarter reached 0.00 compared to expectations of 13.55M by % .
The stock price reacted with a % one-day change and a % five-day change following the earnings release. These movements reflect market reaction in Protalix Biotherapeutics Inc growth trajectory and strategic initiatives.
PLX Earnings Forecast
Looking ahead, Protalix Biotherapeutics Inc(PLX) remains a focal point for investors seeking growth opportunities. Analyst forecasts for 2025/Q2 project quarter revenue of 13.49M and an EPS of .
However, recent estimate revisions provide additional context. Over the past three months, revenue estimates for FY2025 have been Revise Upward by 5.09%, while EPS estimates have been Revise Upward by 16.66%. For the upcoming , revenue estimates have been adjusted Go Down by -1.20% . These revisions correlate with a % change in stock price over the same period, suggesting potential buying opportunities for investors who believe in Protalix Biotherapeutics Inc long-term fundamentals.
The relationship between earnings forecast revisions and stock price movements is critical for investors. Positive revisions in revenue or EPS often signal strengthening fundamentals, making temporary price dips attractive entry points. Conversely, downward revisions may reflect short-term challenges.
Estimate Revision
The chart shows the correlation between PLX's stock price and earnings forecast revisions. Positive revisions in Revenue or EPS often strengthen the stock's fundamentals, making price dips potential buying opportunities.
Revenue Estimates for FY2025
Revise Upward
+5.09%
In Past 3 Month
Revenue Estimates for Q2 2025
Revise Upward
+16.66%
In Past 3 Month
Stock Price
Go Down
-1.20%
In Past 3 Month
1Y
3Y
5Y
Annual FY 2025
Currency: USD
1Y
3Y
5Y
--
Revenue Estimate-Annual FY 2025:57.91M
--
EPS Estimate-Annual FY 2025:0
—
Stock Price1.64
Get winning stock picks in minutes
PLX Revenue and EPS Performance: A Historical Perspective
Protalix Biotherapeutics Inc revenue and earnings per share (EPS) performance over recent quarters provides a clear picture of its financial health. Below is a detailed breakdown of the company’s earnings history, showcasing actual results, analyst estimates, and surprise percentages for key fiscal quarters:
FY2025Q2 (2025-08-14,Pre-Market):
EPS: (Actual) vs.0.03 (Estimate) (%)
Revenue: 0.00 (Actual) vs. 13.55M (Estimate) (%)
Price Reaction: %(1-Day), %(5-Day)
FY2025Q1 (2025-05-09,Pre-Market):
EPS: -0.05 (Actual) vs.0.08 (Estimate) (-162.50%)
Revenue: 10.00M (Actual) vs. 21.60M (Estimate) (-53.73%)
Price Reaction: -40.48%(1-Day), -42.21%(5-Day)
FY2024Q4 (2025-03-17,Pre-Market):
EPS: 0.09 (Actual) vs.0.07 (Estimate) (28.57%)
Revenue: 18.22M (Actual) vs. 18.75M (Estimate) (-2.81%)
Price Reaction: 9.37%(1-Day), 11.16%(5-Day)
Earnings Reaction
The chart below shows how PLX performed 10 days before and after its earnings report, based on data from the past quarters. Typically, PLX sees a +6.94% change in stock price 10 days leading up to the earnings, and a -0.44% change 10 days following the report. On the earnings day itself, the stock moves by -6.98%. This data can give you a slight idea of what to expect for the next quarter's release.
For example, in MAR/2025, the stock changed -15.12% on the day following the earnings release and then changed by -5.81% over the next 10 days. These patterns provide investors with valuable insights into potential price movements and help inform trading strategies around earnings events.
Transcript Summary
Protalix Biotherapeutics Inc (PLX) Q1 2025 Earnings Call Summary
Negative
2025-05-10
The earnings call reveals several concerns: missed EPS expectations, increased R&D expenses, and significant supply chain costs. While revenue from selling goods increased, the cost of goods sold rose dramatically, indicating potential operational inefficiencies. The Q&A session highlighted uncertainties in regulatory outcomes and vague management responses, further undermining confidence. Despite some positive revenue growth, the lack of a share repurchase program and financial instability suggest a negative outlook for the stock price.
Protalix Biotherapeutics Inc (PLX) Q1 2025 Earnings Call Summary
Neutral
2025-05-09
The earnings call summary presents a mixed picture: strong revenue growth and improved net loss are positive, but rising costs, regulatory uncertainties, and lack of shareholder return plan weigh negatively. The Q&A session reveals management's evasive responses on key issues, adding uncertainty. While revenue from key partnerships is promising, the absence of clear guidance and potential supply chain challenges temper optimism. The stock price is likely to remain stable, as positive and negative factors balance out, resulting in a neutral sentiment.
Protalix Biotherapeutics Inc (PLX) Q4 2024 Earnings Call Summary
Neutral
2025-03-18
The earnings call provided mixed signals. Financial performance showed strong revenue growth and net income improvement, but concerns arose from declining R&D and SG&A expenses, increased income taxes, and competitive pressures. The Q&A revealed uncertainties about revenue guidance and product differentiation. While debt repayment and increased cash position are positive, the lack of clear guidance and competitive challenges temper enthusiasm. Overall, the sentiment is neutral, indicating a likely limited stock price movement.
Protalix Biotherapeutics Inc (PLX) Q4 2024 Earnings Call Summary
Neutral
2025-03-17
The earnings call presents mixed signals. Basic financial performance shows growth in product sales but a significant drop in R&D revenue. The company's financial health is stable with debt repayment and reduced expenses, but increased taxation poses a concern. Market strategy and product development updates lack clarity, as seen in the Q&A. The refusal to provide guidance and vague responses may worry investors. However, the overall financial metrics and shareholder returns remain stable, leading to a neutral sentiment.
Protalix Biotherapeutics Inc (PLX) Q4 2024 Earnings Call Summary
Positive
2025-03-17
The earnings call revealed strong financial performance, with a 75% revenue increase and a shift from net loss to net income. The company's debt-free status and reduced expenses further improve financial health. Despite unclear guidance on Elfabrio, strategic focus on rare renal diseases and ongoing partnerships with Chiesi provide growth potential. The market reaction is likely positive, driven by strong earnings and future revenue growth expectations.
Protalix BioTherapeutics, Inc. (PLX) Q3 2024 Earnings Call Summary
Neutral
2024-11-14
The earnings call presents a mixed picture: strong revenue growth and debt repayment are positives, but competitive pressures, clinical development risks, and supply chain challenges pose concerns. The Q&A section reveals management's uncertainty about trial specifics and market factors, which adds to the neutral sentiment. Despite revenue growth, the lack of new partnerships or guidance changes, coupled with economic factors, suggests a limited impact on stock price.
People Also Watch
CZWI
Citizens Community Bancorp Inc
15.740
USD
+4.24%
BAER
Bridger Aerospace Group Holdings Inc
1.990
USD
+10.56%
PSQH
PSQ Holdings Inc
1.980
USD
+1.02%
OGI
Organigram Global Inc
1.590
USD
-3.05%
FEIM
Frequency Electronics Inc
31.290
USD
+7.27%
TUSK
Mammoth Energy Services Inc
2.210
USD
+0.45%
GPRO
GoPro Inc
1.260
USD
-3.82%
SRI
Stoneridge Inc
7.800
USD
+3.45%
PLBY
Playboy Inc
1.650
USD
+1.23%
PAYS
Paysign Inc
5.440
USD
-3.03%
FAQ
What were the key highlights of PLX’s latest earnings report for FY2025Q2?
PLX reported its FY2025Q2 earnings on 2025-08-14, showcasing a revenue of 0.00 against an estimate of 13.55M, resulting in a 0% surprise. The EPS was 0, surpassing the expected 0.03 by 0% . The stock experienced a 0% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.
How did PLX’s stock price react after the FY2025Q2 earnings release?
What are the revenue and EPS estimates for PLX for 2025/Q2?
How does PLX’s stock price correlate with earnings forecast revisions?
What should investors expect from PLX’s next earnings report?